BCDA
HEALTHCAREBioCardia Inc
$1.11+0.01 (+0.91%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving BCDA Today?
No stock-specific AI insight has been generated for BCDA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.00$2.92
$1.11
Fundamentals
Market Cap$12M
P/E Ratio—
EPS$-1.23
Dividend Yield—
Dividend / Share—
ROE-9.5%
Profit Margin—
Debt / Equity—
Trading
Volume15K
Avg Volume (10D)—
Shares Outstanding10.9M
BCDA News
20 articles- BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance PathwaysGlobeNewswire Inc.·May 8, 2026
- BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D™ Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy ProceduresYahoo Finance·Apr 28, 2026
- BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart FailureYahoo Finance·Apr 20, 2026
- BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart FailureYahoo Finance·Apr 2, 2026
- BioCardia, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 26, 2026
- BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid ...Yahoo Finance·Mar 25, 2026
- BioCardia Reports 2025 Business Highlights and Financial ResultsYahoo Finance·Mar 24, 2026
- BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026Yahoo Finance·Mar 19, 2026
- BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDAYahoo Finance·Mar 17, 2026
- BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)Yahoo Finance·Mar 3, 2026
- BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the HeartYahoo Finance·Feb 10, 2026
- BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT)Yahoo Finance·Feb 3, 2026
- BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDAYahoo Finance·Dec 16, 2025
- BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard KrasnoYahoo Finance·Dec 3, 2025
- BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure CongressYahoo Finance·Dec 1, 2025
- BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of QualityYahoo Finance·Nov 24, 2025
- BioCardia Reports Third Quarter 2025 Business Highlights and Financial ResultsYahoo Finance·Nov 12, 2025
- BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal TrialYahoo Finance·Nov 10, 2025
- BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025Yahoo Finance·Nov 6, 2025
- BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal TrialYahoo Finance·Oct 30, 2025
All 20 articles loaded
Price Data
Open$1.15
Previous Close$1.10
Day High$1.16
Day Low$1.11
52 Week High$2.92
52 Week Low$1.00
52-Week Range
$1.00$2.92
$1.11
Fundamentals
Market Cap$12M
P/E Ratio—
EPS$-1.23
Dividend Yield—
Dividend / Share—
ROE-9.5%
Profit Margin—
Debt / Equity—
Trading
Volume15K
Avg Volume (10D)—
Shares Outstanding10.9M
About BioCardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapies for cardiovascular disease. The company is headquartered in San Carlos, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—